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Structural determinants of the 
catalytic mechanism of Plasmodium 
CCT, a key enzyme of malaria lipid 
biosynthesis
Ewelina Guca1,7, Gergely N. Nagy2,3,8, Fanni Hajdú2,3, Lívia Marton3,4, Richard Izrael2,3, 
François Hoh5,6, Yinshan Yang5,6, Henri Vial1, Beata G. Vértessy2,3, Jean-François Guichou5,6 & 
Rachel Cerdan1
The development of the malaria parasite, Plasmodium falciparum, in the human erythrocyte, relies on 
phospholipid metabolism to fulfil the massive need for membrane biogenesis. Phosphatidylcholine (PC) 
is the most abundant phospholipid in Plasmodium membranes. PC biosynthesis is mainly ensured by the 
de novo Kennedy pathway that is considered as an antimalarial drug target. The CTP:phosphocholine 
cytidylyltransferase (CCT) catalyses the rate-limiting step of the Kennedy pathway. Here we report 
a series of structural snapshots of the PfCCT catalytic domain in its free, substrate- and product-
complexed states that demonstrate the conformational changes during the catalytic mechanism. 
Structural data show the ligand-dependent conformational variations of a flexible lysine. Combined 
kinetic and ligand-binding analyses confirm the catalytic roles of this lysine and of two threonine 
residues of the helix αE. Finally, we assessed the variations in active site residues between Plasmodium 
and mammalian CCT which could be exploited for future antimalarial drug design.
Malaria is a major global health problem and the most life-threatening parasitic disease1. In 2016, 216 million 
cases of malaria and 445 000 deaths were estimated2. Plasmodium falciparum is the parasite that causes the most 
fatal form of malaria among all species infecting humans. While the widespread antimalarial efforts featured by 
the use of insecticide-impregnated bed nets and the artemisinin-based combination therapies (ACT) yielded a 
marked decrease in malaria incidence until 2015, the rate of decline has recently stalled2. Further progress in 
reducing malaria may be compromised due to the emergence of artemisinin resistant parasites3,4. Therefore, it is 
necessary to search alternative antimalarial therapeutics involving novel targets and mechanisms of action.
During the symptomatic erythrocytic stage of P. falciparum, the parasite relies on phospholipids to build the 
membranes necessary for intense cell division. The major phospholipid is phosphatidylcholine (PC) accounting 
for 40–50% of the total phospholipid content and the parasite possesses its own enzymatic machinery to produce 
PC5,6. The de novo Kennedy pathway is the main route for the PC synthesis in P. falciparum and has been identi-
fied as a pharmacological target for the treatment of malaria7–10. Recently, a link has been established between the 
level of lysophosphatidylcholine, a major supplier of choline for the Kennedy pathway, and the sexual stage differ-
entiation in P. falciparum11. This emphasizes the importance of phospholipid biosynthesis at different stages of the 
parasite development. The second step of the PC biosynthesis process catalyzed by CTP:phosphocholine cytidyl-
yltransferase (CCT) [EC: 2.7.7.15] is rate limiting and essential for the survival of the murine parasite at its blood 
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stage12,13. Partial inhibition of PfCCT is also part of the mechanism of action of antimalarial compounds targeting 
lipid biosynthetic pathways14,15. CCT transfers a cytidylyl group from CTP to phosphocholine (ChoP) via a mech-
anism involving the sequential binding of both substrates to form a ternary complex16–19. This leads to the forma-
tion of CDP-choline (CDPCho) by the nucleophilic attack of the ChoP phosphomonoester on the α-phosphate 
of CTP and the release of pyrophosphate (PPi) as an additional product19,20. CCTs are amphitropic enzymes 
that display a several-fold activity increase upon binding to phosphatidylcholine depleted membrane surfaces by 
relieving an auto-inhibitory contact between its catalytic and membrane binding domains21,22. Most eukaryotic 
CCTs contain a single catalytic and membrane binding domain and form dimers22. In contrast, the gene of PfCCT 
underwent a domain duplication event and thus encodes two catalytic and two membrane binding domains 
connected by a disordered interdomain segment16,23 (Fig. 1a). The N-terminal (C1) and C-terminal (C2) catalytic 
domains share 91% sequence identity over 180 amino-acids. To date, only two high resolution crystal structures 
of Rattus norvegicus CCT (RnCCT) catalytic domain were determined, both in complex with CDPCho20,24. The 
first RnCCT crystal structure showed an α/β Rossmann fold for the catalytic domain conserved in cytidylyltrans-
ferase enzymes and allowed the identification of key enzyme interactions with CDPCho20. The second crystal 
structure of the RnCCT catalytic domain was solved in the presence of the amphipathic auto-inhibitory (AI) helix 
of the membrane binding domain24. These structural and additional biochemical studies25,26 provided evidence 
that the regulatory mechanism of CCT involves a direct interaction between the C-terminal helix αE of the cat-
alytic domain and the AI helix. Many aspects of the CCT structure and regulatory mechanism have been uncov-
ered recently21,22,27. However, 3D structures of the free and substrate-bound enzyme were still to be determined 
for the detailed understanding of the catalytic mechanism of CCT.
Figure 1. PfCCT domain organization and structure of PfCCT(581–775). (a) Domain organization of the full 
length PfCCT, PfCCT(528–795) and PfCCT(581–775) catalytic domain constructs, lacking a lysine-rich loop between 
residues 720–737. N-Cap segment (N), Catalytic domains (C), membrane binding domains (M) and lysine-rich 
sequences (K) are indicated. (b) Cartoon representation of PfCCT(581–775) dimer (PDB:4ZCT). Nomenclature 
of secondary structures follows that of RnCCT20 and B. subtilis GCT34,36 in this order β1-L1-αA-β2-αB-L2-
αC-L3-β3-L4-αD-β4-L5-αL-β5-L6-αE. The N-terminal disordered part assigned by NMR is depicted as blue 
dashed line (see also Supplementary Fig. S2). The flexible loop L5 lacking a lineage-specific lysine-rich region 
(720–737) is indicated by a violet dashed line. (c,d) Close-up of dimer interface regions. Residues involved in 
inter-monomer contacts (dashed line) are shown as sticks. Primes indicate residues and secondary structures of 
the other monomer.
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Here, we present the crystal structures of the catalytic domain of the P. falciparum enzyme (PfCCT) in the 
free form, as well as in complex with its substrate ChoP or fragments (CMP and choline) and with the product 
CDPCho, thereby visualizing the free and the ChoP-complexed states of CCT for the first time. The set of high 
resolution structures allowed the identification of active site conformational changes along the catalytic reaction. 
Structural insights complemented with kinetic and ligand binding analyses elucidate the role of key active site 
residues in the PfCCT mechanism of action. The presented results allow detailed structural characterization of a 
potential antimalarial target of the phospholipid metabolism pathway of Plasmodium and may help for the design 
of specific inhibitors.
Results
Biochemical characterization of PfCCT catalytic domain construct. In order to provide structural 
insights into the mechanism of action of PfCCT, we set out to crystallize the constitutively active C-terminal cata-
lytic domain of PfCCT. Several constructs were tested and our attempts were successful only in case of PfCCT(581–775) 
that corresponds to the exact region visible in the crystal structure of RnCCT (PDB: 3HL4)20 (Fig. 1a). While this 
construct proved to be highly crystallogenic, activity assays revealed its reduced catalytic rate together with an 
increased KM for CTP as compared to the longer construct PfCCT(528–795) used in our previous studies16 (Table 1 
and Supplementary Fig. S1). We further assessed the functionality of PfCCT(581–775) by characterizing its substrate 
and product binding ability. Its affinity for CDPCho (Kd = 47 µM) reported by isothermal titration calorime-
try (ITC) displayed a moderate attenuation as compared to the one of PfCCT(528–795) (Kd = 34 µM) (Table 2 and 
Supplementary Fig. S1). Saturation Transfer Difference Nuclear Magnetic Resonance (STD-NMR) experiments 
indicated STD signal of CTP, ChoP and CDPCho bound to PfCCT(581–775) at 1 mM, 4 mM and 1 mM concentra-
tions, respectively (Supplementary Fig. S1). This latter result is consistent with previously observed unusually low 
ChoP affinity of PfCCT16. We concluded that PfCCT(581–775) is compatible with substrate and product recogni-
tion and may be amenable to structural studies provided that its compromised enzymatic function is taken into 
account in structure-based interpretations. It is likely that the drop of PfCCT(581–775) enzyme activity is due to the 
elimination of the C-terminal flanking part as similarly located truncations in the RnCCT catalytic domain also 
led to severe loss of activity28,29. After unsuccessful efforts to crystallize longer PfCCT catalytic domain constructs 
with an extended C-terminal end, we continued crystallization trials with PfCCT(581–775) and obtained single 
crystals of the free enzyme and in presence of the enzymatically relevant ligands ChoP, CMP and CDPCho as 
well as Cho.
Structure of the free PfCCT C-terminal catalytic domain. The structure of PfCCT(581–775) was deter-
mined at 2.2 Å resolution by molecular replacement using RnCCT structure20 (PDB: 3HL4) as a search model 
(Table 3). The enzyme forms a globular dimer with an α/β Rossmann fold that is well conserved in CCTs and 
other members of the cytidylyltransferase enzyme family (Fig. 1b). Here, the homodimer state likely mimics the 
full-length PfCCT conformation with two almost identical catalytic sites. The dimerization interface of PfCCT 
PfCCT kcat (s−1) KM,CTP (µM) KM,ChoP (µM)
581–775 0.010 ± 0.001 1,100 ± 200 N.D.
528–795a 1.45 ± 0.05 170 ± 20 1,950 ± 100
528–795 (K663A)b 0.0008 ± 0.0002 70 ± 20 N.D.
528–795 (Y626F/Q636A) 0.24 ± 0.01 170 ± 10 1,600 ± 100
528–795 (T761A) 0.0010 ± 0.0001 1,270 ± 90 3,700 ± 400
528–795 (T762A) 0.0010 ± 0.0001 610 ± 70 2,100 ± 200
Table 1. Kinetic parameters of PfCCT enzyme constructs. aExperimental data are from Nagy et al.16. bThe 
kinetic constant of PfCCT(528–795) K663A refer to a phosphohydrolase activity (see Supplementary Fig. S4). 
Values are the mean (±SD) of at least 2 independent experiments. N.D.: not determined.
PfCCT
Kd,CDP-Cho 
(µM)
ΔHCDP-Cho 
(kcal/mol)
−TΔSCDP-Cho
(kcal/mol)
ΔGCDP-Cho 
(kcal/mol)
Kd,CTP 
(µM)
ΔHCTP
(kcal/mol)
−TΔSCTP 
(kcal/mol)
ΔGCTP 
(kcal/mol)
581–775 47 ± 5 −10.5 ± 0.3 4.7 ± 0.4 −5.8 ± 0.1 N.D. N.D. N.D. N.D.
528–795 34 ± 1 −16.1 ± 0.1 10.1 ± 0.1 −6.0 ± 0.2 60 ± 2 −8.6 ± 0.3 3.0 ± 0.4 −5.7 ± 0.1
528–795 
(K663A) 210 ± 60 −11.4 ± 1.5 6.5 ± 1.6 −5.0 ± 1.4 520 ± 50 6.1 ± 9.3 −10.5 ± 0.6 −4.4 ± 0.1
528–795 
(Y626F/Q636A) 22.2 ± 0.2 −12.0 ± 0.2 5.8 ± 0.1 −6.2 ± 0.1 60 ± 2 −10.8 ± 0.1 5.1 ± 0.2 −5.7 ± 0.1
528–795 
(T761A) N.D. N.D. N.D. N.D. 170 ± 35 −7.0 ± 0.8 1.9 ± 1.0 −5.1 ± 0.1
528–795 
(T762A) N.D. N.D. N.D. N.D. 170 ± 12 −10.5 ± 0.7 5.5 ± 0.8 −5.1 ± 0.1
Table 2. Thermodynamic parameters of ligand binding to PfCCT enzyme constructs. Values are the mean 
(±SD) of at least 2 independent experiments, except for PfCCT(528–795) Y626F/Q636A (see Methods). N.D.: not 
determined.
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is mediated by inter-molecular contacts between several structural elements of each chain. Residues of helix αC 
of one chain are in contact with residues of loop L3′, helix αA’ and helix αE’ of the other chain (Fig. 1c,d). In 
addition, residues of helix αE contact residues of helix αE’ and loop L2′. Intermolecular contacts between L3 loop 
residues of both chains include the 681RWVDE685 dimerization motif that is conserved in all cytidylyltransferases. 
We observed a lack of density in loop L5 for nine residues (712IPYANNQK719E738) in a region where a lysine-rich 
insertion (720–737) had been removed from the construct16. The 35 N-terminal amino acids of PfCCT(581–775) 
were also not visible on electron density maps. This part corresponds to the N-terminal pre-catalytic region of 
RnCCT containing two short helices that constitute an ‘N-cap’ by folding on the subsequent conserved catalytic 
core of the enzyme20,24 (Fig. 1a). To obtain structural information on this N-terminal region, we performed 1H-1H 
2D NMR experiments on PfCCT(581–775). The resonances of 33 N-terminal residues were clearly detectable and 
could be assigned on the 1H-1H 2D NOESY spectrum (Supplementary Fig. S2), arguing for their likely disorder. 
Few α-helix specific crosspeaks were found for the 604DSEKNKG610 segment (Supplementary Fig. S2).
Co-crystal structures of CMP-, Cho-, ChoP- and CDPCho-bound PfCCT. The 3D structures of 
PfCCT(581–775) in complex with CMP, Cho, ChoP or CDPCho (Table 3) possess almost identical overall folds as the 
free protein (Fig. 2 and Supplementary Table S1). In all structures, the ligands were found in the active site. The 
occupancy of ChoP was only 50% even when the crystal was obtained after soaking in very high (50 mM) final 
concentration of ChoP, which is in accordance to the very low affinity described above. Minor conformational 
changes were observed in loops L2 and L4 between strand β3 and helix αD. The major change concerned loop L5 
(residues 712–738) that is only visible in the presence of CDPCho (Fig. 2a). In this case, ordered conformation of 
the loop is assisted by the interaction of Y714 with the ligand which is apparently not strong enough with ChoP or 
choline to render loop L5 ordered (Fig. 3). The nucleotide ligands CMP and CDPCho are anchored in the active 
site by several polar contacts, hydrogen bonds and a cation-π interaction of R755 with the cytosine ring (Fig. 3 
PfCCT (PDB: 
4ZCT)
PfCCT-CMP 
(PDB: 4ZCP)
PfCCT-Cho 
(PDB: 4ZCQ)
PfCCT-ChoP 
(PDB: 4ZCR)
PfCCT-CDPCho 
(PDB: 4ZCS)
Data collection
Space group I222 I222 I222 I222 I222
Cell dimensions
a, b, c (Å) 48.5, 74.4, 119.0 50.5, 69.3, 116.4 50.6, 69.4, 119.0 50.6, 69.6, 117.9 115.5,149.8, 176.6
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å)a 63.02–2.22 (2.44–2.22)
58.22–1.98 
(2.03–1.98)
59.92–1.92 
(1.99–1.92)
46.52–1.80 
(1.85–1.80)
113.7–2.45 
(2.51–2.45)
Rsym or Rmerge 0.087 (0.497) 0.059 (0.307) 0.038 (0.511) 0.054 (0.497) 0.032 (0.377)
I/σI 10.7 (3.0) 10.5 (2.8) 15.0 (1.8) 14.3 (1.8) 10.1 (2.5)
CC1/2 0.995 (0.879) 0.999 (0.896) 0.999 (0.737) 0.999 (0.718) 0.997 (0.859)
Completeness (%) 97.9 (97.9) 99.7 (99.7) 99.2 (99.2) 99.6 (99.6) 99.9 (99.6)
Redundancy 4.0 (3.9) 4.6 (4.6) 4.0 (4.0) 6.4 (6.4) 9.3 (9.4)
B-Wilson 17.84 34.40 44.29 39.00 40.80
Refinement
Resolution (Å) 2.22 1.98 1.92 1.80 2.45
No. reflections 10780 13840 16280 18719 52521
Rwork/Rfree 20.21/24.26 20.92/24.71 20.40/22.60 17.89/23.22 18.06/23.41
No. atoms
Protein 1120 1023 1042 1050 6810
Ligands 21 7 11 186
PEG 38
  Water 98 43 63 91 347
B-factors
  Protein 24.3 41.6 50.4 47.1 45.0
Ligands 38.9 69.3 62.4b 34.1
PEG 77.1
Water 28.3 43.7 51.2 53.9 40.8
R.m.s. deviations
  Bond lengths (Å) 0.007 0.008 0.008 0.009 0.018
  Bond angles (°) 1.003 1.104 0.965 1.218 1.970
Ramachandran plot
  Most favored regions (%) 97.58 96.80 98.41 99.18 96.37
Allowed regions (%) 2.42 3.20 1.59 0.82 2.91
Table 3. Crystallographic data and refinement statistics. aValues in parentheses are for the highest resolution 
shell. bThe occupancy of ChoP is 50%.
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and Supplementary Table S2). In contrast, the choline subsite that accommodates Cho, ChoP and the choline 
moiety of CDPCho provides ligand recognition with charged as well as cation-π interactions forming a com-
posite aromatic box30. The coordination of the nucleophile phosphate moiety in ChoP- and CDPCho-liganded 
structures is ensured by V625, K663 and H709 residues. Analysis of these different liganded PfCCT structures 
demonstrates conformational changes for a set of active site residues responsible for ligand accommodation, 
including D623, Y626, Q636, K663, W692, H709, Y714, I740, Y741 and R755.
Deciphering the role of K663 in catalysis by structural, kinetic and thermodynamic analyses. 
K663 is a special active site residue that displays conformational variety in different liganded complexes (Fig. 3e). 
A catalytically essential role of its equivalent residue in RnCCT (K122) had already been demonstrated using 
molecular dynamics (MD) simulations24 and mutagenesis studies31. Moreover, it was suggested that impeding 
its conformational dynamics has a major role in the enzyme regulatory mechanism24. Here, we found that in the 
free and the CMP-bound PfCCT structures, the reliable positioning of the K663 sidechain is precluded due to the 
weak electron density, suggesting its high flexibility or disorder (Supplementary Fig. S3). The presence of Cho in 
the active site at least partially stabilizes the K663 side chain, while ChoP or CDPCho accommodation renders 
this residue fully visualized. The K663 terminal amino moiety points towards the phosphate group of ChoP or 
both phosphate moieties of CDPCho, in somewhat different conformations (Fig. 3e and Supplementary Fig. S3). 
These structural insights showing variable detection and interactions of K663 prompted us to an in-depth defi-
nition of its role throughout the course of the catalytic mechanism. We interrogated the functionality of this 
residue by site directed mutagenesis followed by biochemical analysis. Exchange of K663 to alanine rendered 
PfCCT(528–795) practically inactive (Table 1). The enzymatic activity was monitored by a coupled pyrophosphatase 
(PPase) assay and consisted of two consecutive steps: the cleavage of the byproduct pyrophosphate into two phos-
phates and the addition of phosphates to a nucleotide derivative, resulting a chromophore substance. Surprisingly, 
we observed a remnant enzymatic activity upon PfCCT K663A enzyme addition, even in absence of both the 
ChoP substrate and the PPase auxiliary enzyme (Supplementary Fig. S4). The accumulation of free phosphate 
in the absence of the substrate, ChoP, argued for a CTP phosphohydrolase (CTP → CDP + Pi) activity of the 
K663A mutant (Supplementary Fig. S4). Thus in a straightforward manner, we could conveniently distinguish 
Figure 2. X-ray co-structures of CDPCho-PfCCT, CMP-PfCCT, ChoP-PfCCT and Cho-PfCCT monomers. 
Complexes with (a) CDPCho (PDB: 4ZCS) at 2.45 Å resolution, (b) CMP (PDB: 4ZCP) at 1.98 Å resolution, 
(c) ChoP (PDB: 4ZCR) at 1.80 Å resolution and (d) Cho (PDB: 4ZCQ) at 1.92 Å resolution. In all cases only 
one monomer of a dimer is presented. The ligands (CDPCho, CMP, ChoP and Cho) are shown in sticks with 
electron density around them. The 2Fo − Fc electron density omit maps were contoured at 1.0 sigma around 
the respective ligand within 1.6 Å of the selected atoms. The maps were created using fft function from CCP4 
software49. The dashed black line in (b–d) represents loop L5 which is not visible for these co-structures.
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the cytidylyltransferase from the CTP phosphohydrolase activities in our coupled enzyme assay for PfCCT(528–795) 
and its K663A mutant, respectively. For reliable characterization of ligand interactions of this lysine, we meas-
ured the equilibrium ligand binding of CDPCho and CTP to PfCCT(528–795) K663A (Table 2 and Supplementary 
Fig. S4). CDPCho binding affinity of the mutant suffered a four- to six-fold attenuation as evidenced by ITC 
measurements. An even more drastic effect was observed for CTP binding to K663A mutant where the reduced 
binding affinity was coupled with a fundamental change in the energetics of binding as compared to wild-type 
PfCCT(528–795). The observed endothermic character of binding (ΔHCTP > 0) caused an entropy-favored binding 
mechanism that opposes the definitely exothermic interaction with the wild-type enzyme. This change can reflect 
either the increased conformational entropy due to a poorly defined binding conformation of the triphosphate of 
CTP or to a lesser extent, the solvent release upon binding to the mutated active site. Collectively, K663 appears 
to facilitate multiple steps in the catalytic mechanism. It has a decisive role in ChoP coordination as evidenced 
by its structural contacts (Supplementary Fig. S3 and Table S2) and by its absolute requirement for the classical 
CCT activity with ChoP as substrate. It also substantially contributes to the efficiency of CTP binding to the free 
enzyme.
Comparison of PfCCT and RnCCT structures and functional characterization of residue alterations. 
The PfCCT and RnCCT catalytic domains share 44% sequence identity23 and high structural similarity (Fig. 4a,b). 
This especially holds for the core region of the conserved α/β Rossmann fold indicated by a dashed circle in 
Fig. 4b, that hosts the inner part of the active site accommodating CDPCho. This region, defined by residues 618–
760 in PfCCT displays an all-atom RMSD value of 0.73 Å with the respective region of the RnCCT structure com-
plexed with CDPCho20. CDPCho is found in the same zig-zag position in both PfCCT and RnCCT co-structures 
with only the two methylene groups of this ligand adopting different conformations. The interaction network of 
CDPCho is also largely similar (Fig. 4c). The differences in the catalytic site concern the residues V625, Y626, 
Q636 and V759 of PfCCT corresponding to hydrophobic residues I84, F85, A95 and I200 of RnCCT, respectively 
(Fig. 4d). A notable structural difference involves Q636 sidechain that enables a direct interaction with the ribose 
3′OH moiety in PfCCT, whereas a similar contact in RnCCT is established by an ordered water molecule next 
to A95. Y626 and Q636 constitute the wall of the active site cavity around the hole for the ribose moiety of the 
ligands. Both residues display conformational changes during the course of catalysis (Fig. 3e). The position cor-
responding to Y626 is strictly reserved for aromatic (Y/F) residues in the HxGH nucleotidylyltransferase enzyme 
superfamily because the edge-on orientation of the aromatic sidechain secures the parallel conformation and 
hydrogen bond contacts of the two histidines from the HxGH motif, critical for their proper catalytic function32 
(Supplementary Fig. S5). In a nucleotide-bound form, Q636 forms a hydrogen bridge to Y626, enabled by the 
phenolic OH group of the latter that is additionally present as compared to its RnCCT surrogate F85. In order to 
evaluate the impact of these residue changes, we engineered a Y626F/Q636A double mutant in PfCCT(528–795) to 
Figure 3. Ligand interactions and conformational changes of PfCCT(581–775) upon ligand binding. Close-up 
views of the substrate/product binding sites of PfCCT. (a) CDPCho-PfCCT structure, (b) CMP-PfCCT 
structure, (c) ChoP-PfCCT structure and (d) Cho-PfCCT structure. Ligand interaction residues are labelled and 
showed in stick representation. Interactions with the nucleotide and choline moieties of ligands are represented 
by black and orange dashed lines, respectively. (e) Conformational changes of active site residues Y626, Q636 
and K663 in different ligand complexes of PfCCT(581–775). Binding of nucleotide ligands induces a shift of Q636 
and Y626 from state 1 to state 2. The K663 residue sidechain is not rendered fully visible in the free enzyme as 
well as in Cho and CMP complexes.
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mimic the RnCCT enzyme. This construct displayed a six-fold attenuated catalytic rate together with an unaltered 
KM,CTP value compared to PfCCT(528–795) (Table 1). Thermodynamic analysis revealed unaltered CTP affinity of 
the mutant with a slightly increased favorable binding enthalpy counterbalanced by a larger entropic penalty 
(Table 2). A modest effect of the residue substitutions was uncovered by the analysis of CDPCho binding. A 
somewhat tighter binding of CDPCho was observed in the case of the RnCCT-mimicking construct PfCCT(528-795) 
Y626F/Q636A, accompanied by a decrease of both the favorable enthalpy and the unfavorable entropy compo-
nents (Table 2). The differences observed for CDPCho binding to PfCCT or to the RnCCT-mimicking construct 
may be interpreted by a slightly more constrained CDPCho interaction in the wild-type PfCCT enzyme. This is 
also supported by the reduced flexibility of the nucleotide binding pocket in the CDPCho-PfCCT structure in 
comparison to the CDPCho-RnCCT structure (PDB: 3HL4), as suggested by B-factor values.
Conformational displacement at the PPi binding region contributes to low activity of PfCCT(581–775). 
In contrast to the core region, the peripheral segments of the PfCCT catalytic domain display considerable struc-
tural changes compared to RnCCT. These include the N-terminal flexible segment of PfCCT and the C-terminal 
protruding part consisting of loop L6 and helix αE (Fig. 4b). This C-terminal region contributes to the active site 
assembly by providing contacts between CTP and the strictly conserved CCT signature sequence RTEG(I/V)
ST(S/T) (Supplementary Fig. S6). The terminal two residues of the signature sequence constitute the N-terminus 
of the helix αE and are expected to coordinate PPi at the bottom of the active site20. The displacement of this func-
tionally relevant part leads to the loss of contact between V759 main chain and the cytosine ring and to a ~5 Å 
displacement of T761 and T762 compared to what is observed in RnCCT (Fig. 4d). To probe the functional role of 
these threonine residues, we designed two T/A single point mutants in PfCCT(528–795) and characterized changes 
Figure 4. Structural comparison of PfCCT and RnCCT catalytic domain in complex with CDPCho. (a) 
Sequence alignment of PfCCT(581–775) and the corresponding region of RnCCT. Strictly conserved residues 
are indicated as white letters on red background and similar residues as red letters on white background. The 
secondary structure elements are added above the sequence. We also noted by a star all residues mentioned in 
the text, including active site residues and non-conserved residues. Residue numbers are noted where the lysine-
rich specific loop (720–737) has been removed. The layout was created by ESPript 3.057. (b) Structural alignment 
of PfCCT (violet) and RnCCT (PDB: 3HL4) (light orange) monomers complexed with CDPCho. CDPCho is 
coloured by atoms with green and deep blue carbons in PfCCT and RnCCT complex structures, respectively. 
Dashed circle designates the core region which is highly similar in PfCCT and RnCCT structures. (c) Close-up 
view of the CDPCho interaction network. (d) Superposition of 3 non-conserved active site residues between 
PfCCT and RnCCT and displacement of the signature sequence fragment (PfCCT: 759VSTT762; RnCCT: 
200ISTS203) located at the border of loop L6 and helix αE. Residues V625, Y626 and Q636 in PfCCT correspond 
to I84, F85 and A95 in RnCCT, respectively. Distances between atoms showed by dashed line are in Å.
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in enzyme kinetics and CTP binding. We found that these alterations rendered the enzyme practically inactive, 
coupled with a substantial increase of KM,CTP values from 170 µM for PfCCT(528–795) to 1,270 µM and 610 µM for 
PfCCT(528–795) T761A and PfCCT(528–795) T762A, respectively (Table 1). Nevertheless, analysis of CTP binding to 
these mutants followed by ITC reported a less substantial, three-fold attenuation effect on binding affinity (Kd,CTP 
values in Table 2). Collectively, kinetic analysis and ITC results suggest that while these threonine residues possi-
bly contact CTP and PPi, they have a more prominent contribution to catalysis than to ligand binding.
Discussion
Prior to our study, only two high resolution structures of CCT catalytic domain and six structures of members 
of the Rossmann-folded cytidylyltransferase enzyme family were available from the Protein Data Bank. These 
include ECT (CTP:phosphoethanolamine cytidylyltransferase) and GCT (CTP:glycerol-3-phosphate cytidylyl-
transferase) catalytic domain structures that together with CCT share the conserved fold architecture as well 
as some key active site residues comprising the RTEG(I/V)ST(S/T) and HxGH signature sequences. All these 
enzymes are specialized in the cytidylyl transfer reaction with a hallmark of exploiting basic residues for substrate 
coordination and catalysis31,33–35. The herein presented structural data complemented with biochemical charac-
terization provide an unprecedented step-by-step view of the enzymatic cycle of PfCCT. The structural snapshots 
of subsequent steps of the catalytic mechanism readily identify steric fluctuations and conformational changes 
of individual residues at the choline and nucleotide subsites (Fig. 5). A limitation of the structural set originates 
from the C-terminal truncation of the catalytic domain with the removal of a part of the helix αE and the subse-
quent linker segment. It is very likely that this engineered modification is responsible for the altered orientation 
of the helix αE compared to CCT, ECT and GCT structures which leads to the detachment of its N-terminal T761 
and T762 residues from the vicinity of the active site. We hypothesize that the apparent displacement of these cat-
alytically important threonines may contribute to the low activity of the shortened PfCCT(581–775) construct used 
for crystallographic studies. We suspect that the helix αE in PfCCT(581–775) possesses significant conformational 
freedom in solution and that its observed conformation in the crystal structures is stabilized by crystal packing 
with local αE lattice contacts forming αE homotopic tetramers from different monomers (not shown).
The present structural set together with previously obtained data offers a stepwise understanding of the CCT 
catalytic mechanism (Fig. 5). Binding of CMP, a fragment of CTP substrate, to the free enzyme active site induces 
a major conformational change of R755 with a ~4 Å displacement to provide a cation-π stacking interaction with 
the cytosine group. A similar nucleotide ligand induced movement of the corresponding arginine has previously 
been observed by MD simulations for RnCCT24 and is also seen in ECT and GCT co-structures. In case of PfCCT, 
a flip of the non-conserved Q636 sidechain additionally provides space for the accommodation of the ribose. 
Notably, its alanine counterpart in RnCCT lacks the ability for this sidechain flip. From a drug design perspective, 
targeting Q636 might enhance the selectivity to PfCCT versus human CCT of a future chemical hit compound. 
The burying of the cytosine part is observed in all available cytidylyltransferase structures complexed with nucle-
otide ligands and is expected to contribute to the favorable binding enthalpy. ChoP binding to the choline subsite 
is accomplished by a slight inward movement of I740 and Y741 sidechains. Key residue contacts to ChoP that 
emerge from these movements involve the orientation of K663 towards the phosphate moiety and of W692 to 
provide cation-π interaction to the trimethylammonium moiety (Fig. 5). Loop L5 is not visible at this stage and 
is seen ordered only in the CDPCho product-bound form. The conformational fluctuations of this segment may 
constitute a side-entry of the active site that enables access of ChoP. While the disorder to order transition of loop 
L5 is first observed in the presented PfCCT structures, the flexibility of this loop was also evidenced in RnCCT 
by the comparatively high local B-factors as well as by fluctuations observed in MD simulations with or without 
CDPCho24. Intriguingly, loop L5 hardly establishes contacts to other structural elements, thus its anchoring to the 
active site is presumably fostered by the cation-π and polar interactions of Y714 with CDPCho (Fig. 5). Closure 
of the choline subsite in the CDPCho-bound state is also accompanied by the further inward movement of I740 
and Y741. Meanwhile, K663 moves to coordinate the Pα group in addition to the Pβ group of CDPCho that origi-
nated from ChoP, allowing the phenolic OH of Y714 to coordinate Pβ moiety (Fig. 5). K663 may also be involved 
in the formation of a productive ES1S2 ternary complex and in the catalytic step. Its position and function during 
the transition state remains to be resolved. It may either coordinate nucleophile phosphate of ChoP or provide a 
bridge between the two phosphate moieties directly involved in catalysis, a conformation apparent in CDPCho 
liganded PfCCT and RnCCT structures and reminiscent of the position of K46 in GCT34. So far no CCT structure 
complexed to CTP is available. Structural insights of related GCT:CTP36 and ECT:CTP (PDB: 4XSV) complexes 
reveal that the serine and threonine residues corresponding to T761 and T762 of PfCCT participate in the coor-
dination of CTP phosphate moieties. The mutation into alanine of the threonine residue of BsGCT, equivalent 
to PfCCT T761, results in a pronounced decrease of the enzyme activity37. Our biochemical results indicate the 
importance of these threonine residues in CTP binding and catalysis. Interestingly, MD simulations show that 
the binding of the AI helix represses the dynamics of the Lys122 of RnCCT (Lys663 of PfCCT) but also of helix αE 
which includes serine/threonine counterparts of T761 and T76224.27.
In conclusion, we provide novel structural insights into the PfCCT-catalyzed enzymatic steps that are sup-
ported by biochemical characterization of key elements in CCT action. A detailed knowledge at the molec-
ular level of the catalytic mechanism of PfCCT constitutes the first step to the rational identification of 
efficient and specific inhibitors. The PC biosynthesis pathway is already validated as an antimalarial target at 
the parasite blood-stage15,38. Recently, the activity of this pathway has also been directly linked to P. falciparum 
transmission-stage formation11. Inhibiting PfCCT, the key enzyme of PC pathway, should therefore have a strong 
impact at multiple stages of the parasite development.
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Methods
Cloning, bacterial expression and purification of CCT constructs. The PfCCT cDNA sequence 
(PlasmoDB: PF3D7_1316600) was codon-optimized for expression in E. coli (GenScript). The PfCCT(581–775) 
construct was obtained using previously described PfCCT(528–795) lacking the lysine-rich Plasmodium specific 
loop (720–737)16. The DNA fragment was cloned into the expression vector pET15bTEV (modified from pET15b, 
Figure 5. Structural views of PfCCT active site at the different enzymatic steps. Electronic surface representations 
of the binding pockets (left) reveal polarity and cavity size changes along the enzymatic cycle. Close-up views of 
the active site (right) show key residues superimposed from two consecutive steps of the catalytic mechanism 
revealing the conformational changes upon substrate/product binding. Protein fold is shown in the background 
as cartoon for the later step. Residues from the free enzyme (E) are in grey, from the CMP-bound enzyme in blue, 
from the ChoP-bound enzyme in yellow and from the CDPCho-bound enzyme in violet. The ligands are colored 
as followed: CMP, orange (S1); ChoP, dark pink (S2) and CDPCho green (P1). In the free enzyme, R755 is found 
in two alternative conformations. Note that instead of the proper substrate CTP, CMP is present in the nucleotide 
subsite in E:S1 state. The α and β phosphate moieties of CDPCho are labelled on the relevant panel.
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Novagen) using the NdeI/BamHI sites in order to produce N-terminal 6 × His-tagged protein where the 6 × His-
tag is cleavable by tobacco etch virus (TEV) protease. The Y626F/Q636A double mutant, the T761A, T762A and 
the K663A mutant constructs of His-tagged PfCCT(528–795) were produced by site-directed mutagenesis using 
the QuikChange method (Agilent). Primers were synthesized by Eurofins MWG GmbH. Primer sequences are 
given in Supplementary Table S3. E. coli BL21 (DE3) cells transformed with the plasmid were grown in Luria-
Bertani (LB) broth containing 100 mg.ml−1 ampicillin at 37 °C to OD = 0.6. Protein expression was induced by 
0.5 mM IPTG and bacteria were continuously cultured for 24 h at 16 °C. Cells were harvested and re-suspended 
in lysis buffer containing 20 mM Tris/HCl pH 7.5, 0.15 M NaCl and 2 mM ethanethiol (EtSH). Supernatant 
containing protein was obtained by lysing cells using a French press, followed by centrifugation at 40 000 g for 
1 h. The supernatant was loaded onto a HisTrap HP column (GE Healthcare) pre-equilibrated with lysis buffer. 
His-PfCCT(581–775) was eluted with 150 mM and 250 mM imidazole in lysis buffer. Removal of the His6-tag was 
performed after the affinity column by incubation with recombinant His6-TEV protease for one night at room 
temperature (protease:protein ratio of 1:100 w-w). After concentration, 1 ml of protein sample was further puri-
fied by gel filtration using a HiLoad 16/60 Superdex 200 pg (GE Healthcare) in lysis buffer. Purification of His-
tagged PfCCT(528–795) mutant constructs is described in Nagy et al.16.
Enzyme kinetics. Enzyme activity measurements were performed as described previously, using a contin-
uous coupled colorimetric assay with pyrophosphatase (PPase), purine nucleoside phosphorylase (PNP) auxil-
iary enzymes and the auxiliary substrate 7-methyl-6-thioguanosine (MESG)16,30,39. For CTP substrate titrations, 
CTP concentration was varied between 100 μM and 2 mM while ChoP concentration was kept constant at 5 mM. 
For ChoP titrations, ChoP concentration was varied between 0.5 mM and 20 mM while CTP concentration was 
kept constant at 1 mM. Initial velocities were calculated from the first 10% of the progress curves using phos-
phate calibration as reference16. Due to the low activity of PfCCT(581–775) and PfCCT(528–795) T761A, T762A var-
iants, the enzyme was used at 10 μM concentration and the slope of the absorbance change was determined 
after monitoring the reaction for 20 minutes. For measurements with PfCCT(528–795) K663A the following reagent 
concentrations were used in the enzyme assay: [PPase] = 0.17 U·ml−1, [PNP] = 1.25 U·ml−1, [MESG] = 0.1 mM, 
[Mg2+] = 5 mM and [PfCCT(528–795) K663A] = 10 μM, to yield adequate signal-to-noise ratio (S/N > 10). Three 
independent experiments were performed for CTP and ChoP kinetic titrations of PfCCT(528–795) K663A. Global fit 
of CTP and ChoP kinetic titrations for each enzyme variant was performed in Origin 8.6 using Michaelis–Menten 
equation, to yield a single kcat parameter.
ITC measurements. Calorimetric measurements were performed on an ITC 200 titration calorimeter 
(Malvern) at 20 °C. The protein samples were dialyzed against 20 mM HEPES/NaOH pH 7.5, 100 mM NaCl, 
including 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP) as reducing agent. CTP and CDPCho were diluted 
from a concentrated stock into the dialysis buffer with subsequent pH adjustment. Concentration of the titrating 
nucleotide ligands were determined using molar extinction coefficients 9000 M−1 cm−1 at 271 nm for CTP and 
5000 M−1 cm−1 at 260 nm for CDPCho16. In the experimental setup, the cell of the instrument was filled with pro-
tein and the syringe with the ligand. The titrations typically included 19 steps of injection with 2 μl of ligand per 
injection spaced 180 s apart from each other, with the injection syringe rotating at 750 r.p.m. The data were ana-
lyzed using MICROCAL ORIGIN software following the directions of the manufacturer. To account for dilution, 
the invariant integrated heat value of the last 3–5 data points was subtracted from all data points. The one set of 
independent sites binding model was applied to data for determination of thermodynamic parameters: dissoci-
ation constant (Kd), stoichiometry (N), enthalpy (ΔH) and entropy (ΔS). Due to the low apparent affinity, the N 
value was fixed to a constant value of 1 in CTP titrations to PfCCT(528–795) K663A according to the low c value ITC 
data analysis protocol40,41. For CTP and CDPCho titrations of PfCCT(528–795) K663A, and CTP titrations of T761A 
and T762A variants of PfCCT(528-795), mean and SD from two independent experiments are provided, whereas 
for CDPCho titrations of PfCCT(581–775) and PfCCT(528-795) mean and SD from three independent experiments are 
provided. For PfCCT(528-795) (Y626F/Q636A), errors of model fit to data of a single ligand binding experiment are 
given.
2D 1H NMR Spectroscopy. NMR experiments for the assignments of the flexible part of PfCCT(581–775) were 
recorded at 283 K on a Bruker 700 MHz NMR spectrometer equipped with a cryogenic 5 mm Z-gradient probe 
head. The aqueous samples were containing 0.5 mM unlabeled PfCCT(581–775) in 20 mM Tris/HCl pH 7.5, 150 mM 
NaCl and 2 mM EtSH in 10% D2O as an internal lock. Two-dimensional 1H-1H TOCSY (isotropic mixing: 60 ms) 
and 1H-1H NOESY (mixing time: 200 ms) were performed for the assignments of the backbone and aliphatic side 
chain 1H resonances. Water suppression was achieved with the WATERGATE sequence42 in both experiments. 
NMR spectra were processed using GIFA software43.
Crystallization and diffraction data collection. 10 mg/ml of PfCCT(581-775) with 20 mM of CDPCho 
(final protein concentration 8 mg/ml) in the lysis buffer were screened by commercially available Classics screen 
(NeXtal, Qiagen) by sitting drop method. 200 nl sitting drops were set up using a 1:1 ratio between protein and 
precipitant in 96-well Greiner crystallization plates using a Cartesian dispensing robot44. After one month crys-
tals of protein-CDPCho complex appeared in 0.2 M NaF, 0.1 M HEPES pH 7.5, 20% PEG 3350 at 20 °C. The 
ligand-free PfCCT crystals were grown by the hanging-drop vapor-diffusion method at 4 °C by mixing 1 µl of 
protein solution at concentration of 10 mg/ml and 1 µl reservoir solution (0.08 M NaF, 0.1 M Tris pH 7.5, 24% 
PEG 3350) and appeared after 3 weeks. CMP-bound and ChoP-bound protein crystals were obtained by soaking 
crystals with CMP and ChoP dissolved in lysis buffer (20 mM Tris/HCl pH 7.5, 0.15 M NaCl and 2 mM EtSH). 
To obtain these co-crystals, ligand-free crystals were first grown by the hanging-drop vapor-diffusion method at 
20 °C by mixing 1 µl of protein solution at concentration 8 mg/ml and 1 µl reservoir solution (pH 8.0, 20% PEG 
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4000). Crystals appeared after 2 months and were soaked with 100 mM CMP and 100 mM ChoP (50 mM final 
concentration) for 5 days and 4 weeks, respectively. Cho-bound crystals were obtained by the hanging-drop 
vapor-diffusion method in 0.08 M NaF, 0.1 M Tris pH 7.5, 24% PEG 3350 at 20 °C by co-crystallization with 
50 mM Cho dissolved in the lysis buffer. Crystals appeared after one week and were left to grow for an additional 
three weeks. Crystals were mounted and soaked in oil as cryosolvent, then frozen in liquid nitrogen. Diffraction 
data were collected at beamlines ID29, ID23-1 and ID23-2 of the European Synchrotron Radiation Facilities in 
Grenoble, France. These crystals belong to space group I222 with the asymmetric unit containing one monomer 
in the case of the free, CMP-bound, ChoP-bound and Cho-bound forms, and six monomers in the case of the 
CDPCho-bound form.
Structure determination and refinement. The indexing and integration of obtained data sets were car-
ried out using XDS (Pilatus)45,46. The scaling, merging and calculating of structural factor amplitudes were exe-
cuted using programs TRUNCATE47 and SCALA48 from CCP4 software49. Crystal structures were constructed 
by molecular replacement using Phaser50 with RnCCT (PDB: 3HL4) and free PfCCT (PDB: 4ZCT) as search 
models, followed by model building in Coot51. The structure refinements were done using REFMAC 5.8.007352,53 
and PHENIX 1.9.169254. Molecular graphics representations were created using PyMol55. All the ligand structures 
were created using PRODRG server56. Crystal diffraction data and final refinement statistics were summarized 
in Table 3.
Accession codes. Atomic coordinates and structure factors for the reported crystal structures have been 
deposited in the PDB under ID codes 4ZCT, 4ZCP, 4ZCQ, 4ZCR and 4ZCS for the free, CMP-, Cho-, ChoP- and 
CDPCho-bound PfCCT, respectively.
References
 1. White, N. J. et al. Malaria. Lancet 383, 723–735 (2014).
 2. WHO. World Malaria Report 2016. World Health Organization, 1–186 (2016).
 3. Breman, J. G. Resistance to artemisinin-based combination therapy. Lancet Infect. Dis. 12, 820–822 (2012).
 4. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455–467 (2009).
 5. Botte, C. Y. et al. Atypical lipid composition in the purified relict plastid (apicoplast) of malaria parasites. Proc. Natl. Acad. Sci. USA 
110, 7506–7511 (2013).
 6. Dechamps, S., Shastri, S., Wengelnik, K. & Vial, H. J. Glycerophospholipid acquisition in Plasmodium - a puzzling assembly of 
biosynthetic pathways. Int. J. Parasitol. 40, 1347–1365 (2010).
 7. Vial, H. et al. In Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development (ed Katja Becker) 137–162 
(Wiley-VCH Press, 2011).
 8. Vial, H. J. et al. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc. Natl. Acad. Sci. USA 101, 15458–15463 (2004).
 9. Wein, S. et al. High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death. 
Antimicrob Agents Chemother 61, e00352–00317 (2017).
 10. Wengelnik, K. et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 295, 1311–1314 
(2002).
 11. Brancucci, N. M. B. et al. Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the Human Malaria Parasite 
Plasmodium falciparum. Cell 171, 1532–1544 (2017).
 12. Dechamps, S. et al. The Kennedy phospholipid biosynthesis pathways are refractory to genetic disruption in Plasmodium berghei 
and therefore appear essential in blood stages. Mol. Biochem. Parasitol. 173, 69–80 (2010).
 13. Sen, P., Vial, H. J. & Radulescu, O. Kinetic modelling of phospholipid synthesis in Plasmodium knowlesi unravels crucial steps and 
relative importance of multiple pathways. BMC systems biology 7, 123 (2013).
 14. Gonzalez-Bulnes, P. et al. PG12, a phospholipid analog with potent antimalarial activity, inhibits Plasmodium falciparum 
CTP:phosphocholine cytidylyltransferase activity. J. Biol. Chem. 286, 28940–28947 (2011).
 15. Wein, S. et al. Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br. J. Pharmacol. 166, 2263–2276 
(2012).
 16. Nagy, G. N. et al. Evolutionary and mechanistic insights into substrate and product accommodation of CTP:phosphocholine 
cytidylyltransferase from Plasmodium falciparum. FEBS J. 280, 3132–3148 (2013).
 17. Park, Y. S., Sweitzer, T. D., Dixon, J. E. & Kent, C. Expression, purification, and characterization of CTP:glycerol-3-phosphate 
cytidylyltransferase from Bacillus subtilis. J. Biol. Chem. 268, 16648–16654 (1993).
 18. Sundler, R. Ethanolaminephosphate cytidylyltransferase. Purification and characterization of the enzyme from rat liver. J. Biol. 
Chem. 250, 8585–8590 (1975).
 19. Veitch, D. P., Gilham, D. & Cornell, R. B. The role of histidine residues in the HXGH site of CTP:phosphocholine cytidylyltransferase 
in CTP binding and catalysis. Eur. J. Biochem. 255, 227–234 (1998).
 20. Lee, J., Johnson, J., Ding, Z., Paetzel, M. & Cornell, R. B. Crystal structure of a mammalian CTP: phosphocholine cytidylyltransferase 
catalytic domain reveals novel active site residues within a highly conserved nucleotidyltransferase fold. J. Biol. Chem. 284, 
33535–33548 (2009).
 21. Cornell, R. B. Membrane lipid compositional sensing by the inducible amphipathic helix of CCT. Biochim. Biophys. Acta 1861, 
847–861 (2016).
 22. Cornell, R. B. & Ridgway, N. D. CTP:phosphocholine cytidylyltransferase: Function, regulation, and structure of an amphitropic 
enzyme required for membrane biogenesis. Prog. Lipid Res. 59, 147–171 (2015).
 23. Contet, A. et al. Plasmodium falciparum CTP:phosphocholine cytidylyltransferase possesses two functional catalytic domains and 
is inhibited by a CDP-choline analog selected from a virtual screening. FEBS Lett. 589, 992–1000 (2015).
 24. Lee, J., Taneva, S. G., Holland, B. W., Tieleman, D. P. & Cornell, R. B. Structural basis for autoinhibition of CTP:phosphocholine 
cytidylyltransferase (CCT), the regulatory enzyme in phosphatidylcholine synthesis, by its membrane-binding amphipathic helix. J. 
Biol. Chem. 289, 1742–1755 (2014).
 25. Ding, Z. et al. A 22-mer segment in the structurally pliable regulatory domain of metazoan CTP: phosphocholine cytidylyltransferase 
facilitates both silencing and activating functions. J. Biol. Chem. 287, 38980–38991 (2012).
 26. Huang, H. K. et al. The membrane-binding domain of an amphitropic enzyme suppresses catalysis by contact with an amphipathic 
helix flanking its active site. J. Mol. Biol. 425, 1546–1564 (2013).
 27. Ramezanpour, M., Lee, J., Taneva, S. G., Tieleman, D. P. & Cornell, R. B. An auto-inhibitory helix in CTP:phosphocholine 
cytidylyltransferase hijacks the catalytic residue and constrains a pliable, domain-bridging helix pair. J. Biol. Chem. 293, 7070–7084 
(2018).
www.nature.com/scientificreports/
1 2ScIEnTIFIc REpoRTS |  (2018) 8:11215  | DOI:10.1038/s41598-018-29500-9
 28. Cornell, R. B. et al. Functions of the C-terminal domain of CTP: phosphocholine cytidylyltransferase. Effects of C-terminal deletions 
on enzyme activity, intracellular localization and phosphorylation potential. Biochem. J. 310, 699–708 (1995).
 29. Yang, W., Boggs, K. P. & Jackowski, S. The association of lipid activators with the amphipathic helical domain of CTP:phosphocholine 
cytidylyltransferase accelerates catalysis by increasing the affinity of the enzyme for CTP. J. Biol. Chem. 270, 23951–23957 (1995).
 30. Nagy, G. N. et al. Composite aromatic boxes for enzymatic transformations of quaternary ammonium substrates. Angew. Chem. Int. 
Ed. Engl. 53, 13471–13476 (2014).
 31. Helmink, B. A., Braker, J. D., Kent, C. & Friesen, J. A. Identification of lysine 122 and arginine 196 as important functional residues 
of rat CTP:phosphocholine cytidylyltransferase alpha. Biochemistry 42, 5043–5051 (2003).
 32. D’Angelo, I. et al. Structure of nicotinamide mononucleotide adenylyltransferase: a key enzyme in NAD(+) biosynthesis. Structure 
8, 993–1004 (2000).
 33. Maheshwari, S. et al. Biochemical characterization of Plasmodium falciparum CTP:phosphoethanolamine cytidylyltransferase 
shows that only one of the two cytidylyltransferase domains is active. Biochem. J. 450, 159–167 (2013).
 34. Pattridge, K. A. et al. Glycerol-3-phosphate cytidylyltransferase. Structural changes induced by binding of CDP-glycerol and the role 
of lysine residues in catalysis. J. Biol. Chem. 278, 51863–51871 (2003).
 35. Tian, S. et al. Human CTP:phosphoethanolamine cytidylyltransferase: enzymatic properties and unequal catalytic roles of CTP-
binding motifs in two cytidylyltransferase domains. Biochem. Biophys. Res. Commun. 449, 26–31 (2014).
 36. Weber, C. H., Park, Y. S., Sanker, S., Kent, C. & Ludwig, M. L. A prototypical cytidylyltransferase: CTP:glycerol-3-phosphate 
cytidylyltransferase from bacillus subtilis. Structure 7, 1113–1124 (1999).
 37. Park, Y. S. et al. Identification of functional conserved residues of CTP:glycerol-3-phosphate cytidylyltransferase. Role of histidines 
in the conserved HXGH in catalysis. J. Biol. Chem. 272, 15161–15166 (1997).
 38. Peyrottes, S. et al. Choline analogues in malaria chemotherapy. Curr. Pharm. Des. 18, 3454–3466 (2012).
 39. Marton, L. et al. Molecular Mechanism for the Thermo-Sensitive Phenotype of CHO-MT58 Cell Line Harbouring a Mutant 
CTP:Phosphocholine Cytidylyltransferase. PLoS One 10, e0129632 (2015).
 40. Tellinghuisen, J. Isothermal titration calorimetry at very low c. Anal. Biochem. 373, 395–397 (2008).
 41. Turnbull, W. B. & Daranas, A. H. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? J. Am. 
Chem. Soc. 125, 14859–14866 (2003).
 42. Piotto, M., Saudek, V. & Sklenar, V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. 
Biomol. NMR 2, 661–665 (1992).
 43. Pons, J. L., Malliavin, T. E. & Delsuc, M. A. Gifa V. 4: A complete package for NMR data set processing. J. Biomol. NMR 8, 445–452 
(1996).
 44. Walter, T. S. et al. A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for 
initial screening, automated storage, imaging and optimization. Acta Crystallogr. D Biol. Crystallogr. 61, 651–657 (2005).
 45. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. 
Appl. Crystallogr. 26, 795–800 (1993).
 46. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
 47. French, S. & Wilson, K. On the treatment of negative intensity observations. Acta Crystallogr. Sect. A 34, 517–525 (1978).
 48. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006).
 49. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).
 50. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
 51. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 
(2004).
 52. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta 
Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997).
 53. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 
355–367 (2011).
 54. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. 
Crystallogr. 66, 213–221 (2010).
 55. DeLano, W. L. The PyMOL Molecular Graphics System. http://www.pymol.org, DeLano Scientific, San Carlos, CA, USA (2002).
 56. Schüttelkopf, A. W. & van Aalten, D. M. F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta 
Crystallogr. Section D D60, 1355–1363 (2004).
 57. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, 
W320–324 (2014).
Acknowledgements
This work was supported by the French Agence Nationale de la Recherche (ANR-09-BLAN-0397) and by the 
National Research, Development and Innovation Office (K109486, K119493), the Hungarian Academy of 
Sciences Medinprot program and ICGEB CRP/HUN14-01. The authors thank the support of collaboration visits 
by the French-Hungarian Bilateral S&T Cooperation (TÉT_14_FR-1-2015-0024). This work was also supported 
by the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INBS-05. EG was funded by the 
European Commission FP7 Marie-Curie Initial Training Network “ParaMet” [grant number 290080]. Financial 
support from ÚNKP-16-2 to FHa is gratefully acknowledged. The authors also acknowledge the European 
Synchrotron Radiation Facilities (Grenoble, France) for provision of synchrotron radiation facilities and we are 
grateful to staff scientists for assistance in using the beamlines ID29, ID23-1 and ID23-2. We thank Dr. Karine 
De Guillen for help with the STD-NMR experiments and Dr. Kai Wengelnik for helpful discussions and advices.
Author Contributions
E.G. purified and crystallized the proteins. G.N.N., F. Ha., L.M. and R.I. cloned and purified the mutants, 
performed and analyzed kinetic and ITC experiments. E.G., F. Ho. and J-.F.G. collected diffraction data, built 
and refined the structures. E.G. and Y.Y. performed and analyzed NMR experiments. H.V., B.G.V., J-.F.G. and 
R.C. designed the study and supervised the work. E.G., G.N.N., F. Ha., L.M., R.I., B.G.V. and R.C. wrote the 
manuscript. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29500-9.
Competing Interests: The authors declare no competing interests.
www.nature.com/scientificreports/
13ScIEnTIFIc REpoRTS |  (2018) 8:11215  | DOI:10.1038/s41598-018-29500-9
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
